Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Katsumi Sakamoto is active.

Publication


Featured researches published by Katsumi Sakamoto.


Biological Chemistry | 2006

Mutagenesis and carcinogenesis caused by the oxidation of nucleic acids.

Yusaku Nakabeppu; Kunihiko Sakumi; Katsumi Sakamoto; Daisuke Tsuchimoto; Teruhisa Tsuzuki; Yoshimichi Nakatsu

Abstract Genomes and their precursor nucleotides are highly exposed to reactive oxygen species, which are generated both as byproducts of oxygen respiration or molecular executors in the host defense, and by environmental exposure to ionizing radiation and chemicals. To counteract such oxidative damage in nucleic acids, mammalian cells are equipped with three distinct enzymes. MTH1 protein hydrolyzes oxidized purine nucleoside triphosphates, such as 8-oxo-2′-deoxyguanosine triphosphate and 2-hydroxy-2′-deoxyadenosine triphosphate (2-OH-dATP), to the corresponding monophosphates. We observed increased susceptibility to spontaneous carcinogenesis in MTH1-null mice, which exhibit an increased occurrence of A:T→C:G and G:C→T:A transversion mutations. 8-Oxoguanine (8-oxoG) DNA glycosylase, encoded by the OGG1 gene, and adenine DNA glycosylase, encoded by the MUTYH gene, are responsible for the suppression of G:C to T:A transversions caused by the accumulation of 8-oxoG in the genome. Deficiency of these enzymes leads to increased tumorigenesis in the lung and intestinal tract in mice, respectively. MUTYH deficiency may also increase G:C to T:A transversions through the misincorporation of 2-OH-dATP, especially in the intestinal tract, since MUTYH can excise 2-hydroxyadenine opposite guanine in genomic DNA and the repair activity is selectively impaired by a mutation found in patients with autosomal recessive colorectal adenomatous polyposis.


Cancer Research | 2007

MUTYH-Null Mice Are Susceptible to Spontaneous and Oxidative Stress–Induced Intestinal Tumorigenesis

Katsumi Sakamoto; Yohei Tominaga; Kazumi Yamauchi; Yoshimichi Nakatsu; Kunihiko Sakumi; Kaoru Yoshiyama; Akinori Egashira; Shinobu Kura; Takashi Yao; Masazumi Tsuneyoshi; Hisaji Maki; Yusaku Nakabeppu; Teruhisa Tsuzuki

MUTYH is a mammalian DNA glycosylase that initiates base excision repair by excising adenine opposite 8-oxoguanine and 2-hydroxyadenine opposite guanine, thereby preventing G:C to T:A transversion caused by oxidative stress. Recently, biallelic germ-line mutations of MUTYH have been found in patients predisposed to a recessive form of hereditary multiple colorectal adenoma and carcinoma with an increased incidence of G:C to T:A somatic mutations in the APC gene. In the present study, a systematic histologic examination revealed that more spontaneous tumors had developed in MUTYH-null mice (72 of 121; 59.5%) than in the wild type (38 of 109; 34.9%). The increased incidence of intestinal tumors in MUTYH-null mice (11 tumors in 10 of 121 mice) was statistically significant compared with the wild type (no intestinal tumors in 109 mice). Two adenomas and seven adenocarcinomas were observed in the small intestines, and two adenomas but no carcinomas were found in the colons. In MUTYH-null mice treated with KBrO(3), the occurrence of small intestinal tumors dramatically increased. The mean number of polyps induced in the small intestines of these mice was 61.88 (males, 72.75; females, 51.00), whereas it was 0.85 (males, 0.50; females, 1.00) in wild-type mice. The tumors developed predominantly in the duodenum and in the upper region of the (jejunum) small intestines. We conclude that MUTYH suppresses spontaneous tumorigenesis in mammals, thus providing experimental evidence for the association between biallelic germ-line MUTYH mutations and a recessive form of human hereditary colorectal adenoma and carcinoma.


Cancer Research | 2016

Decreased Expression of Fructose-1,6-bisphosphatase Associates with Glucose Metabolism and Tumor Progression in Hepatocellular Carcinoma

Hidenari Hirata; Keishi Sugimachi; Hisateru Komatsu; Masami Ueda; Takaaki Masuda; Ryutaro Uchi; Shotaro Sakimura; Sho Nambara; Tomoko Saito; Yoshiaki Shinden; Tomohiro Iguchi; Hidetoshi Eguchi; Shuhei Ito; Kotaro Terashima; Katsumi Sakamoto; Masakazu Hirakawa; Hiroshi Honda; Koshi Mimori

Fructose-1,6-bisphosphatase (FBP1), the rate-limiting enzyme in gluconeogenesis, is reduced in expression in certain cancers where it has been hypothesized to act as a tumor suppressor, including in hepatocellular carcinoma (HCC). Here, we report functional evidence supporting this hypothesis, providing a preclinical rationale to develop FBP1 as a therapeutic target for HCC treatment. Three independent cohorts totaling 594 cases of HCC were analyzed to address clinical significance. Lower FBP1 expression associated with advanced tumor stage, poor overall survival, and higher tumor recurrence rates. In HCC cell lines, where endogenous FBP1 expression is low, engineering its ectopic overexpression inhibited tumor growth and intracellular glucose uptake by reducing aerobic glycolysis. In patient specimens, promoter methylation and copy-number loss of FBP1 were independently associated with decreased FBP1 expression. Similarly, FBP1 downregulation in HCC cell lines was also associated with copy-number loss. HCC specimens exhibiting low expression of FBP1 had a highly malignant phenotype, including large tumor size, poor differentiation, impaired gluconeogenesis, and enhanced aerobic glycolysis. The effects of FBP1 expression on prognosis and glucose metabolism were confirmed by gene set enrichment analysis. Overall, our findings established that FBP1 downregulation in HCC contributed to tumor progression and poor prognosis by altering glucose metabolism, and they rationalize further study of FBP1 as a prognostic biomarker and therapeutic target in HCC patients. Cancer Res; 76(11); 3265-76. ©2016 AACR.


Japanese Journal of Radiology | 2014

A case of gastric plexiform fibromyxoma: Radiological and pathological findings

Katsumi Sakamoto; Masakazu Hirakawa; Kazushige Atsumi; Koshi Mimori; Kohei Shibata; Taro Tobo; Hidetaka Yamamoto; Hiroshi Honda

Plexiform fibromyxoma is a relatively new pathological category that consists of a rare group of non-gastrointestinal stromal tumors with a peculiar plexiform growth pattern. We report a case of gastric plexiform fibromyxoma in a 60-year-old man. Gastroscopic examination revealed a gastric submucosal tumor in the antrum. Magnetic resonance imaging (MRI) showed a nodule with distinct signal hyperintensity on T2-weighted images, with strong enhancement peripherally in the early phase to the entire lesion in the delayed phase. Endoscopic ultrasound-guided fine-needle aspiration cytology was performed, and the cytological diagnosis was spindle cell tumor, so partial gastrectomy was performed under a preoperative diagnosis of GIST. The resected tumor demonstrated plexiform architecture, myxoid stroma, prominent vasculature, and spindle cells, reflecting the characteristic findings on MRI. This is the first report to describe radiological findings for gastric plexiform fibromyxoma.


DNA Repair | 2006

MTH1, an oxidized purine nucleoside triphosphatase, prevents the cytotoxicity and neurotoxicity of oxidized purine nucleotides

Yusaku Nakabeppu; Kosuke Kajitani; Katsumi Sakamoto; Hiroo Yamaguchi; Daisuke Tsuchimoto


Annals of Surgical Oncology | 2015

Downregulation of PRRX1 Confers Cancer Stem Cell-Like Properties and Predicts Poor Prognosis in Hepatocellular Carcinoma

Hidenari Hirata; Keishi Sugimachi; Yusuke Takahashi; Masami Ueda; Shotaro Sakimura; Ryutaro Uchi; Junji Kurashige; Yuki Takano; Sho Nanbara; Hisateru Komatsu; Tomoko Saito; Yoshiaki Shinden; Tomohiro Iguchi; Hidetoshi Eguchi; Kazushige Atsumi; Katsumi Sakamoto; Toshiro Doi; Masakazu Hirakawa; Hiroshi Honda; Koshi Mimori


International Journal of Radiation Oncology Biology Physics | 2014

Utility of an Artificial Neural Network for Prediction of Survival in Patients With Esophageal Cancer Treated With Radiation Therapy

Kazushige Atsumi; K. Nakamura; Hidetaka Arimura; R. Hirayama; Tomio Sasaki; Saiji Ohga; Tadamasa Yoshitake; Katsumi Sakamoto; Masakazu Hirakawa; Hiroshi Honda


Interventional Radiology | 2018

Midterm Outcomes and Prognostic Factors of Patients Treated Using Microballoon-Occluded Transarterial Chemoembolization with Miriplatin: A Retrospective Study of 37 Cases

Masakazu Hirakawa; Torahiko Yamanouchi; Satoru Tsuruta; Akihiro Inoue; Hidenari Hirata; Keiji Matsumoto; Katsumi Sakamoto; Hironori Sakai; Koshi Mimori; Hiroshi Honda


International Journal of Radiation Oncology Biology Physics | 2017

Poster ViewingDownregulation of MicroRNA-203 Associated With Radioresistance in Esophageal Squamous Cell Carcinoma Cells

Kotaro Terashima; H. Hirata; H. Wakiyama; R. Uchi; T. Masuda; Katsumi Sakamoto; Masakazu Hirakawa; K. Mimori; Hiroshi Honda


Cancer Research | 2017

Abstract 4411: Loss of fructose-1,6-bisphosphatase expression induces altering glucose metabolism and tumor progression in hepatocellular carcinoma

Hiroaki Wakiyama; Hidenari Hirata; Keishi Sugimachi; Takaaki Masuda; Naoki Hayashi; Yohsuke Kuroda; Shuhei Ito; Hidetoshi Eguchi; Kotaro Terashima; Katsumi Sakamoto; Masakazu Hirakawa; Hiroshi Honda; Koshi Mimori

Collaboration


Dive into the Katsumi Sakamoto's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge